Avecho Biotechnology Limited
AVEFF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.01 | 0.02 | -0.00 | 0.00 |
| FCF Yield | 20.88% | -54.60% | -67.34% | -363.15% |
| EV / EBITDA | -6.23 | -5.84 | 1.80 | 3.72 |
| Quality | ||||
| ROIC | -59.45% | -47.46% | -66.44% | -31.53% |
| Gross Margin | 70.51% | 56.64% | 66.37% | -1,335.20% |
| Cash Conversion Ratio | -1.69 | 0.29 | 0.29 | 2.12 |
| Growth | ||||
| Revenue 3-Year CAGR | 34.15% | -29.70% | -38.65% | -34.22% |
| Free Cash Flow Growth | 235.67% | -431.71% | 77.40% | -594.20% |
| Safety | ||||
| Net Debt / EBITDA | 2.31 | 1.57 | 2.24 | 4.35 |
| Interest Coverage | 0.00 | -40.04 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 1.20 | 2.59 | 1.09 | 4.01 |
| Cash Conversion Cycle | -141.37 | 265.85 | -595.19 | 0.51 |